We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Reference sheet · Viral Peptides · CPC catalog code HIV-013
Composition figures above are derived arithmetically from the published sequence for the unmodified free peptide. Salt forms (commonly trifluoroacetate or acetate), amidation, and other modifications shift the observed mass — always reconcile against the current lot certificate of analysis.
Volumes for a 1 mg vial of HIV-1 gag Polyprotein (121-140) at common working concentrations. Add solvent slowly down the vial wall and swirl — do not vortex or shake.
Reference standards in the Viral Peptides class are typically shipped as lyophilized powder and stored desiccated at −20 °C protected from light. Once reconstituted in bacteriostatic water or the assay-appropriate buffer, aliquot and store at −80 °C to minimize freeze–thaw cycles. Confirm handling requirements against your institutional biosafety and radiation protocols before use.
HIV-1 gag Polyprotein (121-140) sits within the Viral Peptides research class (CPC reference HIV-013). Viral peptides map to functional regions of viral proteins — fusion peptides, receptor-binding domains, protease cleavage sites, and immunodominant epitopes — enabling targeted studies of entry, replication, and immune recognition. Investigators typically incorporate HIV-1 gag Polyprotein (121-140) as a reference standard, tool ligand, or substrate in the assay contexts listed above. Pseudovirus entry, plaque-reduction, protease-activity, and ELISA readouts.
HIV-1 gag Polyprotein (121-140) (CPC catalog code HIV-013) is a synthetic viral / antiviral research peptide in the viral peptides category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.
Published and internal research programs use HIV-1 gag Polyprotein (121-140) as a reference standard in viral peptides workflows — for example, viral fusion and entry-inhibitor screening and viral protease activity and inhibitor discovery. Human clinical evidence is not established.
No. HIV-1 gag Polyprotein (121-140) is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.
In a viral peptides workflow, HIV-1 gag Polyprotein (121-140) is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Pseudovirus entry, plaque-reduction, protease-activity, and ELISA readouts.
Other reference standards in the same class — commonly cross-referenced during assay design and comparator selection.